Fidelity Investments’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-710,681
| Closed | -$53.5M | – | 5624 |
|
|
2022
Q2 | $53.5M | Sell |
710,681
-105,074
| -13% | -$4.67M | 0.01% | 1227 |
|
|
2022
Q1 | $21.9M | Sell |
815,755
-582,848
| -42% | -$19.6M | ﹤0.01% | 1741 |
|
|
2021
Q4 | $66.7M | Sell |
1,398,603
-761,051
| -35% | -$34M | ﹤0.01% | 1299 |
|
|
2021
Q3 | $143M | Sell |
2,159,654
-909,706
| -30% | -$64.8M | 0.01% | 952 |
|
|
2021
Q2 | $239M | Sell |
3,069,360
-3,319,814
| -52% | -$245M | 0.02% | 740 |
|
|
2021
Q1 | $604M | Buy |
6,389,174
+173,811
| +3% | +$20.7M | 0.05% | 370 |
|
|
2020
Q4 | $757M | Sell |
6,215,363
-109,957
| -2% | -$12M | 0.07% | 280 |
|
|
2020
Q3 | $553M | Buy |
6,325,320
+1,246,123
| +25% | +$86.8M | 0.06% | 309 |
|
|
2020
Q2 | $328M | Buy |
5,079,197
+780,559
| +18% | +$45M | 0.04% | 432 |
|
|
2020
Q1 | $192M | Sell |
4,298,638
-542,009
| -11% | -$28.8M | 0.03% | 521 |
|
|
2019
Q4 | $302M | Buy |
4,840,647
+1,253,692
| +35% | +$59.7M | 0.03% | 486 |
|
|
2019
Q3 | $135M | Buy |
3,586,955
+621,461
| +21% | +$27.1M | 0.02% | 772 |
|
|
2019
Q2 | $121M | Buy |
+2,965,494
| New | +$106M | 0.01% | 840 |
|
Fidelity Investments's TPTX Position: Q3 2022 in Review
Fidelity Investments sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 710,681 shares — an estimated $53.5M sold.
Fidelity Investments first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $757M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Fidelity Investments reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Fidelity Investments sold 710,681 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $53.5M.
- Fidelity Investments first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Fidelity Investments's Turning Point Therapeutics, Inc. Common Stock position peaked at $757M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Fidelity Investments's 13F filing for Q3 2022, filed 10 Nov 2022.